Form 4: Agios Pharmaceuticals Director David Scadden Reports Stock and Option Awards

Director David Scadden reports the acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Summary

• On June 20, 2024, David Scadden, a director of Agios Pharmaceuticals, acquired 2,120 restricted stock units and 11,774 stock options.
• The restricted stock units vest on June 20, 2025, and will be delivered within three business days after vesting.
• The stock options, also granted on June 20, 2024, vest as to 100% of the underlying shares on June 20, 2025, and expire on June 20, 2034.
• The exercise price for the stock options is $42.45.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document simply reports the grant of stock options and restricted stock units, which is a routine event.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock and option grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical also utilize stock options and restricted stock units as part of their executive compensation plans.
• The vesting schedules are also fairly standard, with one-year cliffs being common for initial grants.

Stakeholder Impact

• The grant of stock options and restricted stock units can have a positive impact on shareholder value by aligning the interests of management with those of the shareholders.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates